New targeted drug Alyftrek from Vertex Pharmaceuticals

Vertex Pharmaceuticals’ new targeted drug Alyftrek, a triplet that combines vanzacaftor, tezacaftor and deutivacaftor, will be approved by the European Commission (EC) following a positive recommendation in April 2025 by the European Medicines Agency (EMA).

The drug will be available to patients with cystic fibrosis aged 6 years and older with at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in the EU countries.

The European pharmaceutical regulator’s decision was based on the results of a comparative study in which the use of Alyftrek provided non-inferior clinical results to Trikafta (elexacaftor/tezacaftor/ivacaftor). According to the pharmaceutical manufacturer, the new triplet was better at reducing sweat chloride levels.

In addition to the advantage in some efficacy indicators, Alyftrek also has a dosage advantage. Unlike Trikafta, which requires a twice-daily regimen, the new product only needs to be taken once a day.

Vertex Pharmaceuticals is helping and giving hope to cystic fibrosis patients by developing and releasing new drugs every year, protecting their release with a patent. The new drug Alyftrek has patent protection until 2039.